Legal Considerations and Challenges in Longevity Risk Transactions

Jennifer Donohue

This chapter is an extensive revision of the one that appeared in the first edition, as a result of the paradigm shift in the understanding and execution of longevity risk transactions since 2011. For some sceptics the early transactions, largely featuring bespoke longevity swaps with the occasional synthetic buy-in, were largely exploratory and occasionally moving forwards from the known frontiers. Those who engaged in longevity risk transactions were viewed as operating in an uncharted landscape. However, the subsequent six years have seen significant change and development. In May 2017 Prudential Financial provided a US$1.2 billion longevity risk solution, following hard on the heels of Legal & General’s US$900 million longevity swap and reinsurance solution for a UK defined-benefit scheme. These followed five years of a steady and significant increase in the numbers of sizeable transactions executed.

In this chapter we address the legal issues that are central to longevity risk transfer. We shall consider what the primary sources of longevity risk are, including in the life settlement market. We shall also consider how participants manage longevity risk and the types of

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: